Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426954 | 0.88 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1MEN1KMT2AATM | |
| SCHEMBL6427664 | 0.88 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1MEN1KMT2AATM | |
| SCHEMBL6394557 | 0.82 | L3MBTL1 (0.38) | L3MBTL1ALDH1A1MEN1KMT2AATM | |
| SCHEMBL6387572 | 0.79 | ATM (0.35) | L3MBTL1ALDH1A1MEN1KMT2AATM | |
| SCHEMBL6426012 | 0.75 | TSHR (0.50) | L3MBTL1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL6430640 | 0.69 | ALDH1A1 (0.40) | L3MBTL1ALDH1A1GAAKDM4ELMNA | |
| SCHEMBL6393753 | 0.69 | SLC6A2 (0.35) | L3MBTL1ALDH1A1KDM4ELMNASLC6A2 | |
| SCHEMBL6427997 | 0.69 | PKM (0.40) | L3MBTL1ALDH1A1MEN1KMT2AATM | |
| SCHEMBL6394447 | 0.68 | KDM4E (0.31) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL6502963 | 0.67 | DPP9 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | L3MBTL1 4470/4885ALDH1A1 67/4885MEN1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.